Wave Life Sciences, GSK partner on oligonucleotide-based gene therapies
Wave Life Sciences and GSK have forged a partnership to discover and develop oligonucleotide therapeutics, focusing on new genetic targets, for respiratory diseases. The discovery collaboration with an initial four-year research term is expected to advance Wave Life Sciences’ preclinical RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency (AATD), a disease that impacts the […]